1. Home
  2. DRMA
  3. Earnings

AI Earnings Predictions for Dermata Therapeutics Inc. (DRMA)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-2.95%

$0.70

0% positive prob.

5-Day Prediction

-10.70%

$0.64

0% positive prob.

20-Day Prediction

-22.74%

$0.55

0% positive prob.

Price at prediction: $0.72 Confidence: 99.9% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -2.95% -10.70% -22.74% 99.9% Pending
Q2 2026 HOLD -1.75% -6.38% -13.52% 18.9% Pending

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 10, 2026 · 100% conf.

AI Prediction SELL

1D

-2.95%

$0.70

Act: -2.46%

5D

-10.70%

$0.64

20D

-22.74%

$0.55

Price: $0.72 Prob +5D: 0% AUC: 1.000
0001493152-26-050964

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Dermata Therapeutics Provides Corporate Update

and Reports Financial Results for the Third Quarter 2026

- Dermata generates product revenue following the launch of its first commercial product,

Tome™ Foundational Treatment, on August 25, 2026 -

- Tome Skincare ecommerce platform establishes a foundation for product growth through direct-to-consumer sales, subscriptions, and professional skincare channels -

- Positive topline results from a cosmetic clinical study in which participants demonstrated improvements across multiple measures of skin appearance provides clinical support for the commercialization strategy of Tome Foundational Treatment as “Studied Skincare” -

SAN DIEGO, CA, November 10, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare products, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2026.

“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business,” commented Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer. “With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder. We are excited about the early interest in our Tome Foundational Treatment, including approximately 30% of orders generated via subscriptions. We believe our subscribers will help establish the foundation for a scalable business with opportunities to expand consumer awareness, develop recurring revenue through subscriptions, and introduce our products to skincare professionals.”

“Importantly, our strategy extends beyond the launch of a single product. Recently, we initiated a clinical trial evaluating Tome Clearing Treatment, our second planned commercial product for the treatment of acne, which we expect to launch in the first half of 2027,” continued Mr. Proehl.

“Looking ahead, our priorities are focused on increasing brand awareness of Tome, converting consumer interest into sales, expanding our distribution opportunities, and building a broader portfolio of products powered by Bioneedle. We believe our combination of clinical expertise, differentiated skincare technology, and direct-to-consumer commercialization provides an opportunity to build a growing skincare business with multiple potential revenue streams and create long-term value for our shareholders,” concluded Mr. Proehl.

Recent Corporate Highlights

●Launched Tome Foundational Treatment and generated revenue. On August 25, 2026, Dermata officially launched Tome Foundational Treatment, its first commercial skincare product, through its direct-to-consumer website. The launch represents a significant milestone in the Company’s strategic transition to commercial skincare and provides Dermata with its first opportunity to generate revenue from product sales. Tome Foundational Treatment is a once-weekly skin renewal treatment powered by the Company’s Bioneedle technology and is designed to improve the appearance of skin tone, texture, fine lines, and dark spots.

●Announced positive topline results from cosmetic clinical study of Tome Foundational Treatment. In October 2026, Dermata announced positive topline results from its completed cosmetic clinical study evaluating Tome Foundational Treatment in 31 participants over four weeks. The study demonstrated improvements across multiple investigator-assessed measures of skin appearance, including fine lines, hyperpigmentation, radiance, and overall appearance. More than 71% of participants were graded as having overall improvement in skin appearance after just one treatment. The Company believes these results support Tome’s positioning as “studied skincare” and provides clinically supported content to enhance consumer education, strengthen brand credibility, and support future marketing efforts.

●Continued building brand awareness and market visibility for Tome. Surrounding the Tome Foundational Treatment commercial launch, Dermata has focused on introducing Tome to consumers through digital marketing, social media, public relations, and editorial outreach. The Company believes that building awareness of Tome’s Bioneedle technology and once-weekly application format will be important in supporting customer acquisition and expanding its presence in the premium skincare market.

●Advanced development of second commercial skincare product for acne. In October 2026, Dermata announced e

2026
Q2

Q2 2026 Earnings

8-K HOLD

Aug 11, 2026 · 19% conf.

AI Prediction HOLD

1D

-1.75%

$1.06

Act: +27.78%

5D

-6.38%

$1.01

20D

-13.52%

$0.93

Price: $1.08 Prob +5D: 41% AUC: 1.000
0001493152-26-037124

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 –

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

SAN DIEGO, CA, August 11, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.

“Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company,” commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we’ve identified the untapped ‘white space’ to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues in the near future while continuing to build long-term value for our shareholders,” continued Mr. Proehl. “Looking ahead, we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement, and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to come,” concluded Mr. Proehl.

Corporate Highlights

●Attended first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand. In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially launch the Tome brand and provided attendees with more information on the upcoming launch of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa, and wellness professionals with over 400+ brands in attendance.

●Began social media campaign for its new skincare brand, Tome. The Company recently unveiled the Tome brand’s official social media presence as part of the Company’s broader commercial launch strategy. These efforts are designed to increase brand awareness, engage prospective consumers, and support the successful ecommerce launch of the Company’s first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026.

Anticipated Upcoming Milestones

●Launch first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application.

●Continue development of a second DTC product. The Company is also working on its second skincare product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected to launch sometime after its Foundational Treatment.

Second Quarter 2026 Financial Results

As of June 30, 2026, the Company had $4.4 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $3.1 million decrease in cash and cash equivalents for the six months ended June 30, 2026, resulted from $4.9 million of cash used in operations, and $0.1 million of cash used in investing activities, offset by approximately $1.9 million of ATM financing proceeds. The Company expects its current cash resources to be sufficient to fund operations into the fourth quarter of 2026.

Research and development expenses were $0.2 million for the quarter ended June 30, 2026, compared to $0.6 million for the quarter ended June 30, 2025. The $0.4 million decrease in research and development expenses resulted primarily from the Company’s decision to prioritize the commercial launch of its first product, resulting in a decrease in research and development efforts during the three months ended June 30, 2026. As the Company continues to focus on branding, marketing, and manufacturing of its first commercial product, the Company reallocated its resources, including employee efforts, toward the pre-commercial launch and anticipates that research and development expenses will continue to decrease compared to prior periods.

Selling, general and administrative expenses were $2.8 mill

2026
Q1

Q1 2026 Earnings

8-K

May 13, 2026

0001493152-26-022710

false 0001853816

0001853816

2026-01-01 2026-03-31

0001853816

DRMA:CommonStockParValue0.0001PerShareMember

2026-01-01 2026-03-31

0001853816

DRMA:WarrantsExercisableForOneShareOfCommonStockMember

2026-01-01 2026-03-31

0001853816

2026-03-31

0001853816

2025-12-31

0001853816

2025-01-01 2025-03-31

0001853816

us-gaap:StockCompensationPlanMember

2026-01-01 2026-03-31

0001853816

us-gaap:StockCompensationPlanMember

2025-01-01 2025-03-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

xbrli:pure

Exhibit 99.1

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

- Dermata announced their Tome Skincare brand for direct-to-consumer (“DTC”) skincare products -

- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 -

- Raised $2.0 million in net proceeds from it’s at-the-market (“ATM”) financing facility -

SAN DIEGO, CA, May 13, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026.

“Since announcing our strategic pivot in September 2025, we have made meaningful progress toward becoming a direct-to-consumer commercial skincare company,” commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This pivot represents a significant landmark in our mission to deliver safe, effective, and consumer-friendly skincare products. We continue to build on that foundation during the first quarter of 2026 by advancing development of our initial product, refining our brand strategy, and aligning our operations to support commercialization. We are currently finalizing product packaging, putting the finishing touches on the Tome skincare website and getting ready to initiate consumer use studies to provide clinical data to support our upcoming product launches,” Mr. Proehl continued. “As we look ahead, we remain focused on executing our planned mid-2026 launch of our once-weekly Foundational Treatment for skin renewal that we believe will bring an in-office-like treatment into the hands of consumers. We believe this product launch will position Dermata to deliver long-term value for both consumers and shareholders,” concluded Mr. Proehl.

Corporate Highlights

●Announced its new skincare brand, Tome. In March 2026, Dermata revealed its new skincare brand, Tome, which aims to introduce professional skincare at home. The Tome skincare line will emphasize products Dermata believes can become the essential foundation of any well-rounded skincare routine. The Company plans to add multiple products to the Tome skincare portfolio that utilize time-tested remedies to simplify skincare routines, first starting with a once-weekly Foundational Treatment for skin renewal.

●Announced the hiring of Kyra Peckaitis as Vice President of Marketing. In March 2026, Ms. Peckaitis joined the Dermata team to lead its new Tome skincare brand. Prior to joining Dermata, Ms. Peckaitis worked at Coterie helping to build its DTC baby care brand. Ms. Peckaitis brings years of experience in DTC marketing and brand building.

●Raised $ 2.0 million in net proceeds in Q1 2026. The funds raised during Q1 2026 from the Company’s ATM are expected to help fund Dermata’s operations into the first quarter of 2027.

Anticipated Upcoming Milestones

●Launch first DTC product, Foundational Treatment, in the middle of 2026. The Company is finalizing packaging for the upcoming launch of its Foundational Treatment. The Company believes the Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application. The Company anticipates being ready to launch the Foundational Treatment in the middle of 2026.

●Continue to prepare for the launch of a second DTC product. The Company is also working on its second DTC product which is expected to launch after its Foundational Treatment.

First Quarter 2026 Financial Results

As of March 31, 2026, the Company had $6.9 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $0.6 million decrease in cash and cash equivalents for the quarter ended March 31, 2026, resulted from approximately $2.0 million of ATM financing proceeds which were decreased by approximately $0.1 million from equity financing-related expenses, offset by $2.5 million of cash used in operations. The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.

Research and development expenses were $0.4 million for the quarter ended March 31, 2026, compared to $1.3 million for the quarter ended March 31, 2025. The $0.9 million decrease in research and development expenses was the result of $0.7 million of decreased clini

About Dermata Therapeutics Inc. (DRMA) Earnings

This page provides Dermata Therapeutics Inc. (DRMA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on DRMA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: